Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Phenolsulfonic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | CA2 | P00918 | 6/20 | 0.56 |
| ▸ | CA1 | P00915 | 4/20 | 0.56 |
| ▸ | CA12 | O43570 | 3/20 | 0.56 |
| ▸ | CA9 | Q16790 | 3/20 | 0.56 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenolsulfonic Acid SCHEMBL8781961 | 0.94 | LMNA (0.59) | LMNACA2CA1CA12CA9 | |
| Phenolsulfonic Acid SCHEMBL2518118 | 0.94 | LMNA (0.59) | LMNACA2CA1CA12CA9 | |
| Phenolsulfonic Acid SCHEMBL18577736 | 0.94 | LMNA (0.59) | LMNACA2CA1CA12CA9 | |
| Phenolsulfonic Acid SCHEMBL1470053 | 0.94 | LMNA (0.59) | LMNACA2CA1CA12CA9 | |
| Phenolsulfonic Acid SCHEMBL8008849 | 0.94 | LMNA (0.59) | LMNACA2CA1CA12CA9 | |
| Phenolsulfonic Acid SCHEMBL125056 | 0.94 | LMNA (0.59) | LMNACA2CA1CA12CA9 | |
| Phenolsulfonic Acid SCHEMBL11084143 | 0.94 | LMNA (0.59) | LMNACA2CA1CA12CA9 | |
| Phenolsulfonic Acid SCHEMBL15023824 | 0.94 | LMNA (0.59) | LMNACA2CA1CA12CA9 | |
| Phenolsulfonic Acid SCHEMBL11196801 | 0.94 | LMNA (0.59) | LMNACA2CA1CA12CA9 | |
| Phenolsulfonic Acid SCHEMBL32134 | 0.94 | LMNA (0.59) | LMNACA2CA1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11850294-B2 | Buffered microencapsulated compositions and methods | PREMIER DENTAL PRODUCTS COMPANY (US) | 2023-12-26 | — | — | US | claimed |
| US-20220079849-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | FIDELITY DIRECT LENDING LLC, AS ADMINISTRATIVE AGENT | 2022-03-17 | — | — | US | claimed |
| EP-1868940-B1 | OBTAINING AMMONIUM DINITRAMIDE (ADN) CRYSTALS | HERAKLES (FR) | 2017-09-20 | — | — | EP | claimed |
| US-7789980-B2 | Preparation of ammonium dinitroamide (ADN) crystals, ADN crystals and energetic composites containing them | SNPE MATERIAUX ENERGETIQUES (FR) | 2010-09-07 | — | — | US | claimed |
| US-20090090441-A1 | Preparation of Ammonium Dinitroamide (ADN) Crystals, ADN Crystals and Energetic Composites Containing Them | SNPE MATERIAUX ENERGETIQUES (FR) | 2009-04-09 | — | — | US | claimed |
| CN-114380723-A | Para hydroxybenzene sulfonate compound and preparation method and application thereof | 成都益安成贸易有限公司 | 2022-04-22 | — | — | CN | disclosed |
| US-8889161-B2 | Microencapsulated compositions and methods for tissue mineralization | PREMIER DENTAL PRODUCTS COMPANY (US) | 2014-11-18 | — | — | US | disclosed |
| EP-2424488-A2 | MICROENCAPSULATED COMPOSITIONS AND METHODS FOR TISSUE MINERALIZATION | Premier Dental Products Company (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010129309-A2 | MICROENCAPSULATED COMPOSITIONS AND METHODS FOR TISSUE MINERALIZATION | PREMIER DENTAL PRODUCTS COMPNAY (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100272764-A1 | MICROENCAPSULATED COMPOSITIONS AND METHODS FOR TISSUE MINERALIZATION | FIDELITY DIRECT LENDING LLC, AS ADMINISTRATIVE AGENT | 2010-10-28 | — | — | US | disclosed |
| US-7789980-B2 | Preparation of ammonium dinitroamide (ADN) crystals, ADN crystals and energetic composites containing them | SNPE MATERIAUX ENERGETIQUES (FR) | 2010-09-07 | — | — | US | disclosed |
| US-20090090441-A1 | Preparation of Ammonium Dinitroamide (ADN) Crystals, ADN Crystals and Energetic Composites Containing Them | SNPE MATERIAUX ENERGETIQUES (FR) | 2009-04-09 | — | — | US | disclosed |
| EP-0125641-B1 | ALKANOYLOXYBENZENESULFONATE SALT PRODUCTION | ETHYL CORPORATION (US) | 1987-03-04 | — | — | EP | disclosed |
| US-4544503-A | REACTING HYDROXY BENZENESULFONATE WITH CARBON MONOXIDE AND OLEFIN | ETHYL CORPORATION (US) | 1985-10-01 | — | — | US | disclosed |
| US-4537724-A | Alkanoyloxybenzenesulfonate salt production | ETHYL CORPORATION (US) | 1985-08-27 | — | — | US | disclosed |
| EP-0125641-A2 | Alkanoyloxybenzenesulfonate salt production | ETHYL CORPORATION (US) | 1984-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11850294-B2 | Buffered microencapsulated compositions and methods | CHMP4B, LIPA, APOB | PTGS1 3812/4885LMNA 930/4885CA2 690/4885 |
| US-20220079849-A1 | BUFFERED MICROENCAPSULATED COMPOSITIONS AND METHODS | CHMP4B, LIPA, APOB | PTGS1 3812/4885LMNA 930/4885CA2 690/4885 |
| US-20100272764-A1 | MICROENCAPSULATED COMPOSITIONS AND METHODS FOR TISSUE MINERALIZATION | SOST, PHOSPHO1, CAPG | PTGS1 3734/4885LMNA 646/4885CA2 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.